Repare Therapeutics Presents Phase 1 Data on Camonsertib with Radiotherapy at ASTRO
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, recently announced promising data from a study evaluating camonsertib, an oral small molecule ATR inhibitor, in combination with palliative radiation…
SunLink Health Systems, Inc. Reports Fiscal 2024 Q4 and Annual Financial Results
SunLink Health Systems, Inc. (NYSE American: SSY) today reported a loss from continuing operations of $652,000 (or $0.09 per diluted share) for the fourth fiscal quarter ended June 30, 2024,…
Lupin Partners with Celnova to Distribute Orphan Drug NaMuscla
Lupin Limited, a leading global pharmaceutical company, has announced that its subsidiary, Lupin Atlantis Holdings SA, has entered into a distribution agreement with Celnova Pharma for the commercialization of its…
FDA Approves KarXT, a PureTech-Invented Treatment for Schizophrenia in Adults
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company committed to improving the lives of patients with serious diseases, announced today that KarXT (a combination of xanomeline and…
Odyssey Therapeutics Announces Formation of Scientific Advisory Board
Odyssey Therapeutics, Inc., a biotechnology firm at the forefront of developing next-generation precision immunomodulators for inflammatory conditions, has announced the establishment of its Scientific Advisory Board (SAB). This board features…
GE HealthCare Gets FDA Approval for Flyrcado PET Radiotracer to Improve Coronary Artery Disease Diagnosis
GE HealthCare (Nasdaq: GEHC) has received U.S. Food and Drug Administration (FDA) approval for Flyrcado™ (flurpiridaz F 18) injection, marking a significant advancement in positron emission tomography (PET) myocardial perfusion…
Artera to Present MMAI Platform Insights for Oligometastatic Prostate Cancer at ASTRO 2024
Artera, a pioneer in multimodal artificial intelligence (MMAI) for prognostic and predictive cancer testing, is set to present two oral abstracts at the 2024 American Society for Radiation Oncology (ASTRO)…
Dupixent (dupilumab) Becomes the First Biologic Treatment Approved in the U.S. for COPD Patients
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi have announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) as an add-on maintenance treatment for adults with inadequately…
FDA Approves Bristol Myers Squibb’s COBENFY for Adult Schizophrenia
Bristol Myers Squibb (NYSE: BMY) has received approval from the U.S. Food and Drug Administration (FDA) for COBENFY™ (xanomeline and trospium chloride), marking a significant advancement in the treatment of…
FDA Approves Dupixent as the First Biologic Treatment for COPD in the U.S
The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype and…
Tagrisso Receives U.S. Approval for Unresectable Stage III EGFR-Mutated Lung Cancer Patients
AstraZeneca’s Tagrisso (osimertinib) has received U.S. approval for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), whose disease has…
Roche’s Gazyva Shows Superior Phase III Results in Lupus Nephritis Treatment
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III REGENCY study of Gazyva®/Gazyvaro® (obinutuzumab) in patients with active lupus nephritis. The study revealed that…